Currently, though there are several strategies targeting the mutated cysteine in KRAS (G12C; http://clinicaltrials.gov/ct2/show/NCT03600883), the frequency of the KRAS G12C mutation is much lower in CRC than in lung adenocarcinoma2. The gene discussed is KRAS; the disease is colorectal carcinoma.